The link...

http://phx.corporate-ir.net/phoenix.zhtml?c=83674&p=irol-newsArticle&ID=1652274&highlight=

Marina Biotech Starts Cohort 2 of Its Phase 1b START-FAP Clinical Trial of CEQ508
Data Review Committee Determines CEQ508 Well Tolerated in Cohort 1 Patients
BOTHELL, WA, Jan 25, 2012 (MARKETWIRE via COMTEX) --Marina Biotech, Inc. (NASDAQ: MRNA), a leading nucleic acid-based drug discovery and development company, today announced that Cohort 2 in the Dose Escalation Phase of the START-FAP (Safety and Tolerability of An RNAi Therapeutic in Familial Adenomatous Polyposis) clinical trial with CEQ508 will begin enrolling patients in the next several weeks at Massachusetts General Hospital (MGH) in Boston. The Company also noted that it has successfully transferred all GMP-related stability testing to a contract services organization.

"Three patients completed Cohort 1 of the study last year," stated Alan W. Dunton, M.D., Consulting Chief Medical Officer at Marina Biotech. "CEQ508 was well tolerated by patients with FAP and the Data Review Committee, comprised of the Principal Investigator, Co-Investigator and myself, unanimously agreed that the study should proceed to Cohort 2. CEQ508 has the potential to be a safe and efficacious therapeutic for a patient population with no currently approved pharmaceutical alternative."

"We are encouraged by the positive safety results from the first cohort and the advancement this represents for CEQ508 and the tkRNAi platform overall," stated Richard Ho M.D.-Ph.D., Executive Vice President, Research and Development at Marina Biotech. "The oral delivery of CEQ508, a highly potent oligonucleotide therapeutic, is unique in the RNAi and nucleic acid space. As proper for a Phase I study and a first-in-class therapeutic, the Cohort 1 dose level is below that expected to result in robust inhibition of beta-catenin messenger RNA, the gene target for CEQ508. However, data collected for Cohort 1 indicates the potential for exposure of CEQ508 throughout the entire intestinal tract which is important for not only FAP but any disease that involves the gastrointestinal system. We look forward to collecting additional safety data in Cohort 2."

About CEQ508

CEQ508 is the first drug candidate in a novel class of therapeutic agents utilizing the transkingdom RNA interference (tkRNAi) platform. CEQ508 comprises attenuated bacteria that are engineered to enter into dysplastic tissue and release a payload of short-hairpin RNA (shRNA), a mediator in the RNAi pathway. The shRNA targets the mRNA of beta-catenin, which is known to be dysregulated in classical FAP. CEQ508 is being developed as an orally administered treatment to reduce the levels of beta-catenin protein in the epithelial cells of the small and large intestine. Upon enrollment, patients will be placed in one of four dose-escalating cohorts. Following completion of the dose escalation phase, the trial plan calls for a stable-dose phase in which additional patients will receive the highest safe dose. CEQ508 will be administered daily in an oral suspension for 28 consecutive days. For more information please contact clinicaltrials@marinabio.com.

About FAP

CEQ508 is being developed for the treatment of Familial Adenomatous Polyposis (FAP), a hereditary condition that occurs in approximately 1:10,000 persons worldwide. FAP is caused by mutations in the Adenomatous Polyposis Coli (APC) gene. As a result of these mutations, epithelial cells lining the intestinal tract have increased levels of the protein beta-catenin, which in turn, results in uncontrolled cell growth. Proliferation of the epithelial cells results in the formation of numerous (hundreds to thousands) non-cancerous growths (polyps) throughout the large intestine. By age 35, 95% of individuals with FAP have developed polyps and most will experience adverse effects including increased risk of bleeding and the potential for anemia. In more severe cases, obstruction of the intestines, abdominal pain, and severe bouts of diarrhea or constipation can occur. FAP patients are also at an increased risk of various cancers, the most concerning of which is a nearly 100% occurrence of colon cancer if measures are not taken to prevent the formation of polyps. For many patients, complete colectomy (surgical removal of the entire large intestine), usually performed in the late teenage years or early twenties, is the only viable option for treatment. However, surgical intervention is not curative as the risk of polyps forming in the remaining portions of the intestinal tract and in the small intestine continues after colectomy.

About Marina Biotech, Inc.

Marina Biotech is a biotechnology company focused on the development and commercialization of oligonucleotide-based therapeutics utilizing multiple mechanisms of action including RNA interference (RNAi) and messenger RNA translational blocking. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs -- in bladder cancer and malignant ascites. Marina Biotech entered into an exclusive agreement with The Debiopharm Group for the development and commercialization of the bladder cancer program. In addition, Marina Biotech has recently entered into an agreement with Mirna Therapeutics to license its SMARTICLES(R) technology for the delivery of microRNA mimics. Marina Biotech's goal is to improve human health through the development of RNAi- and oligonucleotide-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at http://www.marinabio.com.

Forward-Looking Statements

Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Marina Biotech to obtain additional funding; (ii) the ability of Marina Biotech to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) the ability of Marina Biotech and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) the ability of Marina Biotech and/or a partner to obtain required governmental approvals; and (v) the ability of Marina Biotech and/or a partner to develop and commercialize products prior to, and that can compete favorably with those of, competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Marina Biotech's most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission. Marina Biotech assumes no obligation to update and supplement forward-looking statements because of subsequent events.

Marina Biotech, Inc.
Philip Ranker
Interim Chief Financial Officer
(425) 908-3615
pranker@marinabio.com


SOURCE: Marina Biotech, Inc.

mailto:pranker@marinabio.com

http://www.marketwire.com/press-release/marina-biotech-mirna-therapeutics-announce-license-agreement-development-microrna-based-nasdaq-mrna-1601751.htm

Hi Sprycel.. I agree with you about the facts and for the grammar.. Anyway here is the link and tell me what's your feelings about it.. Cheers.. Davidoff

http://best-online-money-maker.blogspot.com/2011/12/marina-biotech-inc-showed-odd-volume.html

Saturday, December 10, 2011

Marina Biotech, Inc showed an Odd Volume - NASDAQ:MRNA
Marina Biotech, Inc. (NASDAQ:MRNA) witnessed volume of 7.53 million shares during last trade however it holds an average trading capacity of 2.16 million shares. MRNA last trade opened at $0.17 reached intraday low of $0.14 and went +4.19% up to close at $0.174.

MRNA has a market capitalization $6.02 million and an enterprise value at $4.82 million. Trailing twelve months price to sales ratio of the stock was 2.35 while price to book ratio in most recent quarter was 0.27.

The company made a return on asset of -83.87% in past twelve months and return on equity of -539.78% for similar period. In the period of trailing 12 months it generated revenue amounted to $2.46 million gaining $0.14 revenue per share. Its year over year, quarterly growth of revenue was 358.20%.

According to preceding quarter balance sheet results, the company had $1.07 million cash in hand making cash per share at 0.03. Moreover its current ratio according to same quarter results was 0.47 and book value per share was 0.62.

Looking at the trading information, the stock price history displayed that its S&P500 52 Week Change illustrated 26.31% where the stock current price exhibited down beat from its 50 day moving average price of $0.25 and remained below from its 200 Day Moving Average price of $0.73.

MRNA holds 34.60 million outstanding shares with 32.13 million floating shares where insider possessed 25.16% and institutions kept 3.50%.

Posted by Make Money at 4:46 PM

This link for SPRYCEL...



http://lifetechcapital.com/ltc/2011/12/marina-mrna-downgrade-12-08-11/

Marina (MRNA) Downgrade 12-08-11
Posted in Marina Biotech (MRNA) | Comments Off

Downgrading to Avoid/Sell Due to Program Delays
Recent Financings Continue to Weigh Heavily on Stock
Expected Reverse-Split Could Add to Pressure
Download Full 30-Page Report with Important Disclosures: MRNA Downgrade 12-08-11
1.) Development for FAP and Bladder Cancer Slower Than Anticipated: On June 9, 2011 Marina announced the dosing completion of the first 3-patient cohort in its START-FAP (“Safety and Tolerability of An RNAi Therapeutic in Familial Adenomatous Polyposis”) Phase I trial for CEQ508. The second cohort, which will receive 10x the initial dose, was expected to commence dosing in Q3 2011. Marina now expects doing for the second cohort to start in early-2012. Additionally, on November 29, 2011 Marina announced that their joint R&D team with Debiopharm had advanced a lead DiLA2 formulation and multiple UsiRNA candidates for their bladder cancer program. While this is a positive development for the program, Marina stated that the R&D team expects to select the lead candidate in early-2012, which is significantly later than anticipated. These delays in the development timelines have resulted in reductions to our financial model.
2.) Financings Continue to Weigh on Stock: Marina Biotech’s financing in May brought much needed cash to the company but at the cost of very heavy dilution. In addition to the issuance of the 22.3M shares in the base unit and the 22.3M shares available through the Series B unit warrants, there could be up to an additional 44.6M shares that could potentially be issued from Series A warrants after 1 year at $0.39. As of June 30, 2011, 7,121,500 of the Series B Warrants had been exercised, and in July 2011, an additional 15,172,000 of the Series B Warrants were exercised prior to their July 12, 2011 expiration date.This resulted in 22,293,500 addition shares of dilution and 22,293,500 of additional Series A warrants exercisable at $0.39 after one year. In addition, Marina announced on October 17, 2011 that they had entered into a purchase agreement with an institutional investor, whereby the investor committed to invest at Marina’s option, for up to 30 months, up to $15 million of equity capital. Again, this brings much needed capital to Marina, but adds to the dilution from the previous financing.
3.) Reverse-Split Nearly Certain: On November 30, 2011 Marina announced that NASDAQ had granted the company until January 31, 2012 to establish a closing bid price of its common stock of $1.00 or more per share for a minimum of 10 consecutive business days. Given the stock’s recent performance, future dilution concerns from both the warrant overhang and the equity purchase agreement and lack of catalysts until “early 2012”, we believe it is highly unlikely that Marina will regain the minimum bid requirement without executing a reverse-split, which could put additional pressure on the shares.
4.) Downgrading to Avoid/Sell with $0.10 Price Target: While we continue to believe in Marina’s RNAi science and pipeline opportunities, delays in development timelines combined with additional dilution from recent financings and the risks of a reverse-split has negatively impacted our financial models. Therefore, we are downgrading our recommendation to Avoid/Sell (from Neutral) and reducing our target to $0.10 (from $0.30) based on a 35x multiple on projected 2015 earnings adjusted for the additional shares with a risk discount of 55%.
Download Full 30-Page Report with Important Disclosures: MRNA Downgrade 12-08-11

Stock News
Print Last updated 10/16/2011 1:05 PM PT
(20 min delay)

IBD Stock News for
Ener1 Inc (HEV): Earnings Report Focus


Find out how IBD Rates:
HEV

FUNDAMENTAL
Ener1 Inc will report quarterly earnings on January 01. Ener1 Inc has an Earnings Per Share Rating of 39 from IBD, meaning that recent earnings growth has outperformed 39% of all stocks in IBD's database. In its latest quarter, profit grew 25%. In the last three quarters, profit growth has averaged %. In its latest quarter, sales grew 110% to $23.08 million. Focus on stocks showing strong quarterly earnings growth in recent quarters, at least 25% or more. IBD studies of past market winners showed big earnings and sales growth in recent quarters before big price moves. Ener1 Inc's annual profit margin is -88.9%. That means the company is generating -88.9 cents in profit for each $1 in sales.
TECHNICAL
Ener1 Inc is 95.02% off its 52-week high. In the past four weeks, Ener1 Inc is up 50%. Year-to-date, it's down 91.25%. IBD research has consistently shown that stocks showing strong relative price performance in the market have the best chance of being market leaders. Rather than try to catch stocks on sale, target the leading price performers in the market. Ener1 Inc has an Up/Down volume ratio of 0.9 which indicates that volume on down days is exceeding volume on up days. A ratio above 1.0 implies positive demand for shares.
Ener1 Inc's volume % change is -51.5%. That means volume is on pace to be 51.5% below average. A stock's volume percent change can tell you if institutional investors are fueling a stock's gain or decline. Big volume always gives them away. Big investors like mutual funds, banks and insurance companies account for about 75% of the trading volume each day on the exchanges so it's important to pay attention to what they're buying and selling.
Ener1 Inc's stock price is $0.29 and it has a 50-day average volume of 2,839,000 shares. It's generally best to focus on higher-priced, liquid names rather than low-priced, illiquid ones. Mutual funds and other big investors rarely look at stocks priced under $10 that are thinly traded. Institutional investors generally prefer liquid names so they can buy and sell easily.
TOP STOCKS

Dollar Tree Inc (DLTR)
RS Rating 98
EPS Rating 96
Go to Full Stock Checkup
TOP 3 STOCKS IN INDUSTRY GROUP
DPW
HRBN
AZZ
GENERAL MARKET
The best time to buy stocks is when the major stock indexes are in an uptrend. Target your buys to firms showing strong earnings and sales growth in recent quarters thanks to an innovative new product or service. Stocks like this will generally be trading closer to new high ground. In the early stages of a new rally, stocks staging technical breakouts in heavy volume from sound bases have a good chance of becoming market leaders.
Sometimes, a market rally will come under pressure when there are increasing signs of institutional selling in the market. Institutional selling is seen by a rising number of distribution days, or heavier-volume declines, by the major stock indexes. Selling like this can stop a market rally in its tracks. When the outlook turns to market rally under pressure, it's time to assess stocks in your portfolio and consider locking in partial or full profits. And if you have a small loss in a stock, consider selling to minimize losses.
Cash is a good place to be when the major stock indexes are in a correction. Market corrections occur due to heavy institutional selling in the market. Distribution days, or heavier-volume declines, in the indexes are generally a sign of institutional selling. When the market tide is flowing negative, it's a risky environment for new buys.
ABOUT HEV
MANUFACTURES RECHARGEABLE LITHIUM-ION BATTERIES AND BATTERY SYSTEMS FOR ENERGY STORAGE
KEY NEWS
Hot Stock: Ener1 Inc, Shares Gain 3.6% (HEV)

HI everybody.. What's your recos about HEV in the next quotes sessions ? Should i stay or should i go... Thanks for your answers cause the frenchy is a bit lost...

http://www.cnn.com/video/#/video/us/2011/10/10/tsr-sylvester-bad-ener1-green.cnn

IBD Stock News for
Ener1 Inc (HEV): Earnings Report Focus


Find out how IBD Rates:
HEV

FUNDAMENTAL
Ener1 Inc will report quarterly earnings on January 01. Ener1 Inc has an Earnings Per Share Rating of 38 from IBD, meaning that recent earnings growth has outperformed 38% of all stocks in IBD's database. In its latest quarter, profit grew 25%. In the last three quarters, profit growth has averaged %. In its latest quarter, sales grew 110% to $23.08 million. Focus on stocks showing strong quarterly earnings growth in recent quarters, at least 25% or more. IBD studies of past market winners showed big earnings and sales growth in recent quarters before big price moves. Ener1 Inc's annual profit margin is -88.9%. That means the company is generating -88.9 cents in profit for each $1 in sales.
TECHNICAL
Ener1 Inc is 95.51% off its 52-week high. In the past four weeks, Ener1 Inc is up 35.2%. Year-to-date, it's down 92.11%. IBD research has consistently shown that stocks showing strong relative price performance in the market have the best chance of being market leaders. Rather than try to catch stocks on sale, target the leading price performers in the market. Ener1 Inc has an Up/Down volume ratio of 0.8 which indicates that volume on down days is exceeding volume on up days. A ratio above 1.0 implies positive demand for shares.
Ener1 Inc's volume % change is -10.2%. That means volume is on pace to be 10.2% below average. A stock's volume percent change can tell you if institutional investors are fueling a stock's gain or decline. Big volume always gives them away. Big investors like mutual funds, banks and insurance companies account for about 75% of the trading volume each day on the exchanges so it's important to pay attention to what they're buying and selling.
Ener1 Inc's stock price is $0.26 and it has a 50-day average volume of 2,829,400 shares. It's generally best to focus on higher-priced, liquid names rather than low-priced, illiquid ones. Mutual funds and other big investors rarely look at stocks priced under $10 that are thinly traded. Institutional investors generally prefer liquid names so they can buy and sell easily.
TOP STOCKS

Dollar Tree Inc (DLTR)
RS Rating 98
EPS Rating 96
Go to Full Stock Checkup
TOP 3 STOCKS IN INDUSTRY GROUP
HRBN
DPW
AZZ
GENERAL MARKET
The best time to buy stocks is when the major stock indexes are in an uptrend. Target your buys to firms showing strong earnings and sales growth in recent quarters thanks to an innovative new product or service. Stocks like this will generally be trading closer to new high ground. In the early stages of a new rally, stocks staging technical breakouts in heavy volume from sound bases have a good chance of becoming market leaders.
Sometimes, a market rally will come under pressure when there are increasing signs of institutional selling in the market. Institutional selling is seen by a rising number of distribution days, or heavier-volume declines, by the major stock indexes. Selling like this can stop a market rally in its tracks. When the outlook turns to market rally under pressure, it's time to assess stocks in your portfolio and consider locking in partial or full profits. And if you have a small loss in a stock, consider selling to minimize losses.
Cash is a good place to be when the major stock indexes are in a correction. Market corrections occur due to heavy institutional selling in the market. Distribution days, or heavier-volume declines, in the indexes are generally a sign of institutional selling. When the market tide is flowing negative, it's a risky environment for new buys.
ABOUT HEV
MANUFACTURES RECHARGEABLE LITHIUM-ION BATTERIES AND BATTERY SYSTEMS FOR ENERGY STORAGE
KEY NEWS
Glancy Binkow & Goldberg LLP Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against Ener1, Inc.
- BusinessWire 10/08/2011 01:00 PM ET
CHART (HEV)
Ener1 Inc (HEV)
Enlarge Chart
View in MarketSmith®
Chart View: Daily | Weekly

All prices are delayed at least 20 minutes (10/11/2011)

FUNDAMENTAL PERFORMANCE (HEV)
Current Earnings
EPS Rating 38
3 Yr EPS Growth Rate N/A
Last Quarter EPS % Change 25%
Profit Margin -88.93
Last Qtr Sales % Chg 110%
EPS Due Date N/A
Debt % 27.27
% Shares Held By Management 5.1
Research Development % 36
Next Split Date N/A
TECHNICAL PERFORMANCE (HEV)
Price And Volume
Opening Price N/A
Current Price 0.265
Market Capitalization 44.00 M
50-day Average Volume 2,829,400
Volume % Change -10.2
Up/Down Volume Ratio 0.8
Price % Change (4 Weeks) 35.2
Price % Change (YTD) -92.11
Beta 1.26
Industry Group Rank 145
IBD STOCK NEWS: FOR (HEV)
HEV: Industry Group Focus
HEV: Stock Price and Volume Focus
HEV: Earnings Report Focus
HEV: Technical Snapshot
HEV: Supply and Demand Snapshot
HEV: Sponsorship Snapshot
HEV: Sales Snapshot
HEV: Fundamental Snapshot

Ener1 Inc Down 8.6%, Shares Slide into the Red (HEV)
Published on Mon, 10/10/2011 - 10:34
By Mallory Stone in Market movers, hev, ener1 inc, nasdaq:hev, penny stocks

Ener1 Inc (NASDAQ:HEV) is one of today's worst performing penny stocks, down 8.6% to $0.33 on 0.2x average daily volume.Thus far today, Ener1 Inc has traded 421,000 shares, vs. average volume of 2.7 million shares per day. The company traded 3.4 million shares yesterday.

Ener1 Inc share prices have moved between a 52-week high of $5.90 and a 52-week low of $0.09 and are now trading 266% above that low price at $0.33 per share. The 200-day and 50-day moving averages have moved 4.6% lower and 12.72% lower over the past week, respectively.

Ener1 Inc (NASDAQ:HEV) has potential upside of 659.9% based on a current price of $0.33 and analysts' consensus price target of $2.50. The stock should find initial resistance at its 50-day moving average (MA) of $0.43 and further resistance at its 200-day MA of $2.00.

Ener1, Inc. develops and markets new technologies for clean, efficient energy sources including high-energy lithium batteries for hybrid electric vehicles (HEVs), plug in HEVs, and electric vehicles. Through their subsidiaries, the company also develops commercial fuel cell products and nanotechnology-based materials and manufacturing processes for batteries and other applications.

By Mallory Stone
mstone@fnno.com

ON OCT 10 2011 IN PENNY STOCKS BY ADMIN | NO COMMENTS
Ener1, Inc. (NASDAQ:HEV) witnessed volume of 3.40 million shares during last trade however it holds an average trading capacity of 3.25 million shares. HEV shares opened at $0.39 reached intraday low of $0.31 and went -8.65% down to close at $0.358.

HEV shares price distanced by +44.40% from 20 days average, -18.54% from SMA50 and -82.31% from SMA200. Similarly, the shares performance calculated for a week provided positive result of 155.79%, -3.22% for a month and Year-to-Date performance was -90.55%.

The company has an Enterprise Value of $137.49 billion where in most recent quarter it had a total cash in hand amounted to $19.40 million with a 0.81 book value per share. The beta value of 1.93 signifies to the movement of price with the market condition. The percentage of holdings by the insider in HEV is 0.83%.

Its past twelve months decrease in return from assets was -48.70%, return on equity remained -112.61% and return on investments reached -70.91%. The net profit margin in last 12 months grew down to -154.27% and in most recent quarter debt to equity of 0.70 giving a view of company’s reliance on taking loans.

The Company in past 12 months achieved Gross Profit of $13.87 million where the year to year quarterly revenue growth was 110.33% and Net Income Available to Shareholders reached to $-138.18 million with the diluted EPS of -0.93.



Donot Make Any Investment Decision on the Basis´s of our Reports or Articles. Read Our Full disclaimer
Tags: Ener1, HEV, NASDAQ:HEV